What they do
Evozyne engineers novel proteins by combining deep learning with a high-throughput closed-loop synthesis platform. The company serves the pharmaceutical and agricultural industries, designing enzymes and proteins with targeted functions for therapeutics, sustainability, and industrial chemistry.
The record
- Vertical
- Pharma & Drug Discovery
- Sub-segment
- Protein design
- Product type
- Platform software
- Stage
- Series B
- Headquarters
- Chicago, USA
- Region
- North America
- Founded
- 2020
- Total funding
- $139M raised
Notable investors: Fidelity Management & Research, OrbiMed, Paragon Biosciences, Valor Equity Partners.